T cell receptor–major histocompatibility complex complex presenting cytomegalovirus antigens (TCR–MHC complex (CMV peptide))

The **T cell receptor–major histocompatibility complex (TCR–MHC) complex presenting cytomegalovirus (CMV) antigens** is a multiprotein immune recognition structure at the heart of adaptive antiviral immunity. **T cell receptors (TCRs)**, primarily on CD8+ and CD4+ T cells, bind to specific short peptide fragments of CMV (antigens) that are displayed on the surface of infected host cells by **major histocompatibility complex (MHC)** molecules—class I for CD8+ and class II for CD4+ T cells[1][2][3][4][6][10]. This molecular interaction forms the **TCR–peptide–MHC (pMHC) complex**, which is essential for T cell activation, proliferation, and effector function, leading to recognition and elimination of CMV-infected cells. The diversity and specificity of TCRs allow precise targeting of viral peptides with high sensitivity, but the polymorphic nature of MHC molecules and the immense variation in viral epitopes complicate therapeutic targeting and immune monitoring[1][2][5][8]. This complex is a therapeutic target in adoptive T cell transfer, vaccine engineering, and monitoring of CMV-specific immunity—especially in immunocompromised patients such as transplant recipients where CMV reactivation is a significant threat[5]. Key therapeutic and safety challenges include antigenic diversity, risk of off-target effects, and immune evasion by viral or host mechanisms.

Other names

TCR–pMHC complex (CMV)T cell receptor–peptide–MHC complexTCR–MHC–CMV complexpeptide–MHC–TCR complex

T cell receptor recognition of CMV-derived peptide presented by MHC induces T cell activation Engineered TCR-T cells recognize and lyse CMV-infected cells via this complex Immune checkpoint inhibitors can augment TCR–MHC interactions indirectly by unleashing T cells